Premium
MDMA‐assisted psychotherapy reduces PTSD symptom severity
Author(s) -
Canady Valerie A.
Publication year - 2021
Publication title -
mental health weekly
Language(s) - English
Resource type - Journals
eISSN - 1556-7583
pISSN - 1058-1103
DOI - 10.1002/mhw.32682
Subject(s) - mdma , psychiatry , psychology , hallucinogen , posttraumatic stress , psychotherapist , medicine , clinical psychology
Prior use of selective serotonin reuptake inhibitors (SSRIs) may reduce the effectiveness of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted therapy for post‐traumatic stress disorder (PTSD), say researchers of a recent study who noted that MDMA is close to being considered the first psychedelic drug approved to treat PTSD.